|
 |
European BioPharmaceutical Review
|
| Plasmids prepared from Escherichia coli are fundamental tools in molecular biology, and their most recent applications as DNA medicines for gene therapy and DNA vaccines is a field that has expanded rapidly in the last decade. DNA vaccine candidates are in clinical trials against important diseases such as HIV, tuberculosis, malaria and various cancers; plasmids are also important in gene therapy and anti-cancer therapies. Unlike DNA vaccines, gene therapies can require relatively large doses of purified plasmid DNA. |
Read full article >>
|
|
 |
|
| Rate this article |
You must be a member of the site to make a vote. |
|
Average rating: |
0 |
| | | | | |
|
|
By Dr Rocky Cranenburgh, Molecular Genetics Team Leader, Alexandra Bloor, Molecular Biologist, Matthew Leckenby, Molecular Biologist and Julian Hanak, Director of Production at Cobra Bio-Manufacturing Plc
Rocky Cranenburgh is the Molecular Genetics Team Leader at Cobra. He has a BSc from the University of Bristol and a PhD from the University of Newcastle. Shortly after joining Cobra in 1997, Rocky moved to the Department of Biochemistry at the University of Oxford for a research collaboration, then relocated to Cobra's headquarters at Keele.
Alexandra Bloor is a Molecular Biologist in Cobra's Molecular Genetics Team. She has a BSc from Nottingham Trent University. Alex's research positions prior to joining Cobra in 2001 include the Molecular Genetics Unit of Cambridge University and the Molecular Sciences Institute, La Jolla, California.
Matthew Leckenby is a Molecular Biologist in Cobra's Molecular Genetics Team. He has a Licence en Biologie from Geneva University. Prior to joining Cobra in 2001, Matthew held a studentship at the Institute of Plant Genetics and Crop Plant Research, Germany.
Julian Hanak is the Director of Production at Cobra. He has a BSc from University College London and an MSc from the University College of North Wales. He has held positions in cell and microbial fermentation at the National Institute of Medical Research (Mill Hill), Bioproducts Laboratory (Elstree) and Zeneca Pharmaceuticals (Cheshire). He joined Cobra in 1994 to manage production operations.
|
|
|
|
|
|
 |
Industry Events |
 |
4th Annual Patient Recruitment and Retention in Clinical Trials
13-15 October 2008, Amsterdam
Patient recruitment
is now consuming thirty percent of clinical trial time - more time than any
other clinical trial activity - and almost half of all trial delays result from
patient recruitment problems.
As the
recruiting culture becomes more sophisticated and the forces affecting patient
enrollment grow more numerous and complex, pharmaceutical companies are
striving to discover new strategies to facilitate enrollment in clinical
trials.
With
increasing industry pressure to develop, test and market greater numbers of new
drugs faster, pharmaceutical companies need to perform clinical trials as
quickly as possible. Inefficient patient recruitment processes is a formidable
barrier to pharmaceutical companies' success in launching new products.
Improving the patient recruitment process is imperative to avoid wasted
investments and eliminate costly delays in bringing new drugs to market --
today and even more so in the not-so-distant future. Improved patient
recruitment presents one of the largest opportunities for pharmaceutical
companies to eliminate delays in clinical trials, thereby making it possible to
reduce time to market. With patent time limits and large overheads
meaning that any delays in the development timeline can be disastrous, a good
understanding of how to successfully recruit patients for trials is vital for
any company looking to succeed.
More info >> |
|
 |
News and Press Releases |
 |
Azopharma Product Development Group, Inc
HOLLYWOOD, Fla. – Azopharma Product Development Group, Inc. (“Azopharma”) announced today the addition of innovative state-of-the-art equipment at its formulation and manufacturing division, ApiCross Drug Delivery Technologies in Hollywood, Florida. The most recent acquisition is the MG Futura Capsule Filler which delivers the latest in capsule filling technology. The company has also added a Bausch & Strobel Aseptic Filling Isolator, equipment that is ground-breaking in the powder filling process. These additions support our previously implemented XcelodoseTM powder micro-dosing system. With these technologies, Azopharma is able to provide its clients with all forms of the capsule filling process. The new equipment is part of Azopharma’s recent manufacturing expansion which includes 17 new manufacturing suites for GMP, cytotoxic and aseptic products...
More info >> |
|
 |
